Products / Product lines / Trail Range Professional
Trail Range product line
Companion-Animal Nutrition for Professional Channels
A controlled professional-channel line where documentation, serving specifications, consistent supply and careful product communication matter.
Named finished products remain in development until formula, specification, label and commercial documentation are approved.
Market role
This is a nutritional and wellness platform—not a pharmaceutical line. Veterinary formulation, endorsement and clinical claims require specific documentation.
Products in this line
This line describes a channel and a set of formats. No current product has been allocated to it — a statement about the catalog rather than about the line. The categories below are where products would sit once assigned.
Development categories
Two different kinds of blocker, deliberately kept apart. Specification work is reachable today from public standards, calculation and analysis. A trial is not. Presenting them as the same thing reads as if nothing can proceed.
Supporting digestive function through nutrient supply and fermentable substrate rather than intervention.
Joint comfort and sustained movement in professional and working-channel animals.
Substrate supply for keratinisation, hair growth and epidermal integrity.
Precursor and cofactor supply to pathways implicated in stress physiology.
Energy, protein and hydration matched to the demands of sustained working effort.
Pack formats, serving specifications and documentation suited to clinic, kennel and breeder channels.
Formulation direction
Development inputs, not finished formulas. Each candidate is graded on the published evidence, including the ingredients the evidence tells us to leave out.
Sustained comfortable movement in dogs at risk of, or living with, degenerative joint change.
Lead with
Energy control and body-condition management
EstablishedThe best-evidenced nutritional lever on joint outcomes by a wide margin. Lifetime 25% food restriction pushed median first radiographic hip osteoarthritis from 6 years to 12. In obese dogs, lameness change became detectable from roughly 6% bodyweight loss subjectively and 9% on gait analysis. This is a formulation and feeding-guidance decision, not an additive.
Long-chain omega-3 fatty acids (EPA/DHA)
ModerateThe highest-ranked functional ingredient in a 72-trial meta-analysis, and the only nutraceutical a 2012 systematic review found adequately supported in dogs. Whole-diet enrichment raised serum omega-3 and moved owner-assessed function over six months across 18 practices.
Green-lipped mussel lipid extract
ModerateProduced measurable change in force-plate peak vertical force in a blinded, placebo-controlled trial — objective gait data rather than owner impression.
Basis2023Controlled study
Deprioritise or exclude
Glucosamine and chondroitin sulfate
Counter-indicatedIn the same blinded trial that showed marine lipids moving peak vertical force, glucosamine/chondroitin performed similarly to placebo, and the 2022 meta-analysis reported a marked non-effect. Category convention, not evidence, keeps this pairing in products.
Claim ceiling. Nutrient contribution and normal structure-function only. Joint or mobility improvement claims name a body system beyond nutritive value and read as drug claims.
Substantiation required. A controlled trial on the finished formula in the target population using validated outcome measures, plus analytical verification and stability data for the active fraction.
Nutrient and protein digestibility, faecal consistency and volume, and hindgut fermentation.
Lead with
Fibre matrix — beet pulp and mixed fermentable/insoluble sources
ModerateThe strongest evidence in this category sits with fibre rather than microbial ingredients. Beet pulp raised dry matter and total dietary fibre digestibility and lowered wet faecal output versus cellulose and Miscanthus, with a documented trade-off against crude protein digestibility that formulation must balance.
Protein quality and digestibility
EstablishedConsensus veterinary guidance treats diet as the first-line intervention in chronic enteropathy, with hydrolysed and fibre-enriched formulations showing the highest response rates. Formulate on protein quality rather than crude protein alone.
Deprioritise or exclude
Probiotics as a headline ingredient
EmergingA systematic review of 17 canine trials found a very limited and possibly clinically unimportant effect with moderate-to-high risk of bias, and consensus panels give probiotics only a weak recommendation. Effects are strain- and dose-specific and cannot be extrapolated between strains, so a named deposited strain with its own data is the minimum bar.
Clinoptilolite for canine digestive support
InsufficientGenuinely promising in neonatal calves, but the canine evidence is close to absent — one unblinded ten-dog study in a non-indexed journal. The one controlled canine microbiota trial used a different zeolite with clinoptilolite absent, and the most rigorous trial against a diarrhoea endpoint in any species missed its primary endpoint.
Claim ceiling. Nutritive value only. Digestive-health and stool claims name a body system and require pre-market review.
Substantiation required. Controlled canine data on the specific finished formulation, verified viable counts at end of shelf life for any named strain, and defined inclusion levels.
Substrate supply for keratinisation, hair growth and epidermal integrity.
Lead with
Linoleic acid, zinc and protein adequacy
EstablishedRequirements are settled at standards level, and deficiency of any of the three is associated with a dull, scaly or unkempt coat. Adequacy is the foundation; everything else is incremental.
EPA/DHA
ModerateA systematic review with formal risk-of-bias assessment identified benefit in canine haircoat disorder and allergic dermatitis, though in diseased animals under veterinary management rather than healthy-dog maintenance.
Deprioritise or exclude
Barrier-function positioning
InsufficientA 16-week randomised trial in healthy dogs found graded coat improvement from baseline but no difference between oils and no measurable change in transepidermal water loss — which specifically argues against a skin-barrier claim.
Basis2023Controlled study
Allergy or sensitivity positioning
Counter-indicatedDiagnosis of adverse food reaction requires a veterinarian-supervised elimination trial with controlled rechallenge; serological, salivary and hair testing are not reliable. A product named for seasonal or environmental support must never read as an allergy treatment. Ingredient verification testing matters here regardless: a median 45% of commercial foods tested contained unlisted ingredients.
Claim ceiling. Nutrient contribution to normal skin and coat. No allergy, dermatitis or barrier-repair language.
Substantiation required. Formulation records against published requirements, analytical ingredient verification, and a controlled coat-scoring study on the finished product.
Precursor and cofactor supply to pathways implicated in stress physiology.
Lead with
L-tryptophan
EmergingThe best-supported option in a thin field, and only as an adjunct. Appraised evidence rests on two adequately designed low-risk-of-bias studies and supports a supporting role alongside behavioural management — the authors state explicitly it is not enough as a sole intervention.
Deprioritise or exclude
Alpha-casozepine
EmergingA structured appraisal found no evidence of effect in short-term situational use, and rated the longer-term evidence limited, weak and at high risk of bias. Disclose the appraisal wherever the ingredient appears.
L-theanine and magnesium
InsufficientNo controlled canine trial of L-theanine was located in the indexed literature, and no study of magnesium for canine anxiety was located at all. Their presence in competitor products is not evidence.
Basis2015Observational study2018Observational study2017Observational study2017Systematic review
Claim ceiling. This is the sharpest regulatory hazard in the portfolio. Anxiety is a recognised disease state, so calming language can move a food toward unapproved new animal drug status. Treat as nutrient contribution only.
Substantiation required. A randomised, blinded, placebo-controlled trial on the finished formulation with validated behavioural and physiological endpoints, plus ingredient safety at the fed dose.
Work capacity, thermal tolerance and inter-session recovery in dogs performing repeated physical work.
Lead with
Energy density and fat level matched to work type
EstablishedEnergy demand dominates and is context-dependent — measured requirements in racing endurance dogs ranged from roughly 9,000 to an extrapolated 13,800 kcal/day between race legs, driven by load, terrain and temperature rather than distance. Higher fat suits endurance work; balanced macronutrients suit sprint work.
Palatable oral electrolyte for voluntary intake
ModerateA flavoured electrolyte solution more than doubled voluntary fluid intake versus plain water in working detection dogs in a hot environment, making palatability-driven intake a legitimate design objective in its own right.
Basis2017Controlled study
Deprioritise or exclude
Performance or thermoregulatory claims from hydration
InsufficientThe same trial that doubled voluntary intake detected no effect on core body temperature or olfactory search performance. Intake is the demonstrated outcome; performance is not.
Basis2017Controlled study
Claim ceiling. Nutrient and energy contribution. No performance, endurance or recovery outcome claims.
Substantiation required. Energy density and digestibility data, a controlled feeding trial in the intended working population with objective work and recovery endpoints, and field voluntary-intake data.
Evidence map
These sources guide standards, ingredient review and study design. They do not automatically substantiate an unfinished product.
10 sources · 2025 back to 2006
Association of American Feed Control Officials
Scope. Required label elements, the standardized nutritional adequacy statement formats, and what constitutes misbranding.
Supports. Gives the exact prescribed wording for each substantiation route and confirms that an incorrect adequacy statement, or a disease claim without an approved drug, is misbranding.
Does not establish. Does not carry force of law on its own — AAFCO models bind only where a state has adopted them, and AAFCO approves, certifies and endorses nothing.
Primary source ↗Frontiers in Veterinary Science
Scope. Six-week block-randomised, double-blinded, placebo-controlled trial in 75 owned dogs measured against force-plate peak vertical force.
Supports. Objective gait evidence that marine lipid extracts can shift weight-bearing, and that glucosamine/chondroitin at 30 mg/kg/day performed similarly to placebo.
Does not establish. Does not extend beyond six weeks, found no significant between-group difference on subjective scoring, and was supported by a supplement manufacturer.
Primary source ↗Université de Montréal / International Journal of Molecular Sciences
Scope. Screened 1,578 publications and pooled 72 trials across nine categories of natural health compound in dogs and cats with osteoarthritis.
Supports. Ranks long-chain omega-3 fatty acids as the lead functional ingredient by effect size, and de-prioritises glucosamine–chondroitin.
Does not establish. Does not validate any commercial formulation; the authors flag subjective outcome tools, groups often under ten animals, and wide variation in dose and duration.
Primary source ↗In Vivo
Scope. Systematic review of randomised controlled EPA/DHA studies in dogs and cats with Cochrane RoB2 risk-of-bias assessment; 23 studies included.
Supports. Identifies benefit in canine allergic dermatitis and haircoat disorder among included trials — the strongest single citation for an EPA/DHA coat rationale.
Does not establish. Does not establish effect size, dose or duration for a healthy-dog maintenance product; benefit was found in diseased animals under veterinary management.
Primary source ↗Journal of Veterinary Internal Medicine
Scope. Screened 165 studies, including 17 in vivo canine trials, grading design quality and risk of bias; stool consistency was the most reported outcome.
Supports. Establishes stool consistency as the practical primary outcome for canine digestive research and the need for strain-level data.
Does not establish. Does not support a general probiotic efficacy claim in dogs — the authors found a very limited and possibly clinically unimportant effect, with moderate-to-high risk of bias throughout.
Primary source ↗Journal of Animal Science / Kansas State University
Scope. Replicated Latin square in 12 Beagles comparing three fibre sources at 10% inclusion with total faecal collection.
Supports. Quantifies the fibre trade-off directly: beet pulp raised dry matter and total dietary fibre digestibility and lowered wet faecal output versus cellulose and Miscanthus.
Does not establish. Does not demonstrate a clinical gut-health benefit; beet pulp also lowered crude protein digestibility and produced softer stools, in 12 healthy laboratory dogs at one inclusion level.
Primary source ↗Frontiers in Veterinary Science
Scope. Randomised cross-over field study in seven working dogs comparing plain water, flavoured oral electrolyte solution and subcutaneous fluids.
Supports. Shows flavoured electrolyte solution more than doubled voluntary fluid intake versus water, making palatability-driven intake a legitimate design objective.
Does not establish. Does not demonstrate any performance or thermoregulatory benefit — no effect was detected on body temperature or search performance.
Primary source ↗Veterinary Clinics of North America: Small Animal Practice
Scope. Review of nutritional physiology across canine work types, covering dietary fat, glycogen repletion, protein and ageing working dogs.
Supports. The macronutrient design logic for work-type-specific formulation — higher fat for endurance, balanced macronutrients for sprint work, post-exercise carbohydrate for repeated efforts.
Does not establish. Does not rest on trial evidence for all work types; the authors state that studies for agility, field-trial and detection dogs are rare, so those recommendations are extrapolated.
Primary source ↗National Research Council / National Academies Press
Scope. Consensus requirements, adequate intakes and recommended allowances for every essential nutrient in dogs and cats, across life stages.
Supports. The quantitative floor and ceiling for formulating canine diets and complementary products.
Does not establish. Does not establish requirements, doses or efficacy for probiotics, prebiotics, postbiotics, glucosamine, collagen or any other non-essential ingredient.
Primary source ↗Journal of the American Veterinary Medical Association
Scope. Lifetime paired-littermate study in 48 Labrador Retrievers fed either ad libitum or 25% less of the same diet from eight weeks of age.
Supports. Establishes lifetime energy control as the best-evidenced nutritional lever on joint outcomes — median age at first radiographic osteoarthritis 12 years restricted versus 6 years control.
Does not establish. Does not test any supplement or functional ingredient, uses radiographic rather than pain endpoints, and studied one breed in a controlled colony.
Primary source ↗